AVTX-008
Inflammatory Bowel Disease
PreclinicalActive
Key Facts
About Avalo Therapeutics
Avalo Therapeutics is a U.S.-based, clinical-stage biotechnology company with a mission to develop and commercialize targeted therapeutics for significant unmet needs in immunology and immuno-oncology. Its core strategy involves advancing a pipeline of immune-modulating assets through clinical development, aiming for proof-of-concept data and strategic partnerships. The company operates as a public entity, navigating the high-risk, high-reward landscape of drug development, with its valuation heavily influenced by clinical trial catalysts and financing events.
View full company profileTherapeutic Areas
Other Inflammatory Bowel Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Function-based Consortium for IBD | PharmaBiome | Pre-clinical |
| Galapagos Collaboration | Scipher Medicine | Discovery/Pre-clinical |
| TEV-‘574 (TL1A Inhibitor) | Teva | Phase 3 |
| IBD Subclassification | Bio-Me | Research |
| Anti-iRhom2 antibodies | SciRhom | Pre-clinical |
| IBD Multi-omics Dataset | Ovation.io | Commercial |
| Zymfentra™ | Celltrion | Marketed |
| TLR-004 | Tilray | Preclinical |